RxDoctor Payments DataLook up a doctor →

VYVANSE: payments to doctors

Payments that named VYVANSE as the associated drug or biological, reported under the Sunshine Act for program years 20192025.

Total reported
$2.4M
Providers
33,740
Transactions
112,909
Average per transaction
$21

The per-transaction average — $21 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 33,740 providers the average total is $71, but that average hides a very steep distribution.

Companies reporting these payments

CompanyTotal reportedShare
Takeda Pharmaceuticals U.S.A., Inc.$1,926,80980.3%
Shire North American Group Inc$472,94519.7%
← All drugs & devices